rhPTH(1-34)对成骨细胞增殖、Collagen I及Osterix mRNA表达的影响

目的 观察间歇给予重组人甲状旁腺激素(1-34)[rhPTH(1-34)]对体外成骨细胞增殖、I型胶原蛋白(CoHagen I)及Osterix mRNA表达的影响,初步探讨rhPTH(1-34)对体外成骨细胞的作用机制.方法 体外培养新生大鼠成骨细胞,间歇循环给予0、10-11、10-10、10-9、10-8、10-7 M rhPTH(1-34)干预,(24 h为一循环,前12h给药),共2次,用MTT法检测细胞的增殖;RT-PCR法半定量测定成骨细胞Collagen I、Ostefix mRNA的表达.结果 显示rhPTH(1-34)可明显促进成骨细胞的增殖(P<0.05),促进成骨细胞Collagen I和Ostefix mRNA表达(P<0.05),101-9 M增殖、表达最明显,呈剂量依赖关系.结论 rhPTH(1-34)可促进成骨细胞的增殖、分化,可能是通过Collagen I和Ostefix mRNA表达来调节.     

rhPTH(1-34)对成骨细胞增殖、Collagen I及Osterix mRNA表达的影响

目的 观察间歇给予重组人甲状旁腺激素(1-34)[rhPTH(1-34)]对体外成骨细胞增殖、I型胶原蛋白(CoHagen I)及Osterix mRNA表达的影响,初步探讨rhPTH(1-34)对体外成骨细胞的作用机制.方法 体外培养新生大鼠成骨细胞,间歇循环给予0、10-11、10-10、10-9、10-8、10-7 M rhPTH(1-34)干预,(24 h为一循环,前12h给药),共2次,用MTT法检测细胞的增殖;RT-PCR法半定量测定成骨细胞Collagen I、Ostefix mRNA的表达.结果 显示rhPTH(1-34)可明显促进成骨细胞的增殖(P<0.05),促进成骨细胞Collagen I和Ostefix mRNA表达(P<0.05),101-9 M增殖、表达最明显,呈剂量依赖关系.结论 rhPTH(1-34)可促进成骨细胞的增殖、分化,可能是通过Collagen I和Ostefix mRNA表达来调节.     

rhPTH（1-34）对成骨细胞增殖、CollagenⅠ及Osterix mRNA表达的影响

目的观察间歇给予重组人甲状旁腺激素(1-34)[rhPTH(1-34)]对体外成骨细胞增殖、Ⅰ型胶原蛋白(Collagen Ⅰ)及Osterix mRNA表达的影响,初步探讨rhPTH(1-34)对体外成骨细胞的作用机制。方法体外培养新生大鼠成骨细胞,间歇循环给予0、10-11、10-10、10-9、10-8、10-7M rhPTH(1-34)干预,(24 h为一循环,前12h给药),共2次,用MTT法检测细胞的增殖;RT-PCR法半定量测定成骨细胞Collagen Ⅰ、Osterix mRNA的表达。结果显示rhPTH(1-34)可明显促进成骨细胞的增殖(P<0.05),促进成骨细胞Collagen Ⅰ和Osterix mRNA表达(P<0.05),10-9 M增殖、表达最明显,呈剂量依赖关系。结论 rhPTH(1-34)可促进成骨细胞的增殖、分化,可能是通过Collagen Ⅰ和Osterix mRNA表达来调节。     

rhIGF-1对成骨细胞增殖、BMP-2及Cbfa1基因表达的影响

目的通过重组人胰岛素样生长因子(rhIGF-1)对体外成骨细胞增殖、骨形态蛋白-2(BMP-2)及核心结合因子1(Cbfa1)基因表达的影响,探讨rhIGF-1对骨代谢影响的可能机制。方法不同浓度的rhIGF-1(0、10、50、100ng/ml)刺激体外培养的大鼠成骨细胞,采用噻唑蓝(MTT)法检测细胞增殖能力,用半定量RT-PCR法检测成骨细胞BMP-2、Cbfa1基因的表达。结果rhIGF-1可明显促进成骨细胞增殖(P0.05),并促进成骨细胞BMP-2、Cbfa1基因的表达(P0.01),具有浓度依赖性。结论rhIGF-1可促进成骨细胞的增殖、分化及成熟,可能是通过增强BMP-2、Cbfa1基因的表达来实现的。     

胰岛素样生长因子-1对甲状旁腺激素介导成骨细胞增殖及成骨活性的影响

目的：通过构建乳鼠颅盖骨成骨细胞分离培养与鉴定方法,研究胰岛素样生长因子－1（Insulin－like growth factor－1,IGF－1）及IGF－1联合重组人甲状旁腺激素1－34（recombinant human parathyroid hormone 1－34,rhPTH1－34）对成骨细胞增殖及I型胶原蛋白mRNA表达的影响。方法培养乳鼠成骨细胞,并观察其形态及功能,以原代培养乳鼠成骨细胞为实验模型,分空白组、PTH组、IGF－1组及不同浓度IGF－1作用的PTH介导的成骨细胞组（0、10、50、100 ng／L）。通过不同剂量的胰岛素样生长因子－1（0、10、50、100 ng／L）联合10－9 mol／L重组人甲状旁腺素刺激体外培养的成骨细胞,用噻唑蓝（ MTT）法检测细胞的增殖能力,RT－PCR法检测成骨细胞I型胶原蛋白mRNA的表达。结果 PTH和IGF－1均可促进成骨细胞增殖;IGF－1联合PTH可以促进成骨细胞增殖,且具有剂量依赖性。 PTH联合IGF－1使成骨细胞增殖能力增强、I型胶原蛋白mRNA表达增强。 IGF－1可以促进成骨细胞I型胶原蛋白mRNA的表达,且具有剂量依赖性。 IGF－1可以促进成骨细胞I型胶原蛋白mRNA的表达,且具有剂量依赖性。结论 PTH与IGF－1均可刺激成骨细胞增殖和分化,IGF－1可促进PTH对成骨细胞的分化、增殖。两者合用其作用增强,有协同促进作用。     

国产重组人甲状旁腺素(1-34)对绝经后骨质疏松症的治疗作用研究

目的评价国产重组人甲状旁腺素(1-34)治疗绝经后骨质疏松症的临床疗效和安全性。方法入选绝经后骨质疏松症患者37例,年龄64.2±8.1岁,采用自身前后对照试验设计,每日皮下注射重组人甲状旁腺素(1-34)20μg,同时口服钙尔奇D600 0.6g/d,试验时间6个月,观察患者治疗前后骨密度变化、骨折发生情况,以及血尿常规、肝肾功、电解质、心电图改变等。结果试验期间有1例脱落;经过6个月治疗后,患者L1骨密度增加23.2%(P<0.05),L2骨密度增加18.0%(P<0.05),L3骨密度增加12.5%(P<0.05),L4骨密度增加19.9%(P<0.05),腰椎平均骨密度增加17.8%(P<0.05),股骨颈骨密度增加2.2%(P>0.05),大粗隆骨密度降低6.0%(P>0.05),Wards区骨密度降低1.3%(P>0.05);试验期间新发骨折2例,1例右肱骨骨折,另1例腰椎压缩骨折,无其他严重不良事件发生。结论重组人甲状旁腺素(1-34)治疗绝经后骨质疏松症有效,对腰椎骨密度改善显著,不良反应较轻。     

外源性PTH对摘卵大鼠骨髓PPARγ mRNA表达的影响

目的观察骨质疏松大鼠骨髓微环境PPARγ mRNA表达变化和PTH治疗绝经后骨质疏松症的分子机制。方法雌性大鼠随机分为Sham、OVX和OVX＋PTH（1-34）20μg组，摘卵12周后给药，药后8周处死，观察骨髓脂肪细胞及PPARγmRNA表达变化。结果OVX组大鼠腰椎骨髓腔内脂肪空泡数较Sham组明显增加（P〈0．001），空泡百分面积为Sham组的26．81倍（P〈0．001）。OVX＋PTH20μg组的脂肪空泡数明显减少（P〈0．001），仅为OVX组的18．7％（P〈0．001）；OVX组骨髓PPARγmRNA表达较Sham组明显升高（P〈0．05—0．001），OVX＋PTH（1-34）20μg组PPARγmRNA表达则较不治疗组明显降低（P〈0．05～0．01）。结论OVX骨质疏松大鼠骨髓微环境PPARγmRNA表达上调，PTH对骨质疏松的促进骨形成作用与其抑制骨髓PPARγmRNA表达有关。     

胰岛素样生长因子1对成骨细胞中BMP-2、BMP-7基因表达的影响

目的研究胰岛素样生长因子1(IGF-1)对成骨细胞中BMP-2、BMP-7基因表达的影响,探讨IGF-1促进成骨细胞增殖、分化的分子机理.方法以不同浓度的IGF-1刺激分离培养的大鼠成骨细胞,提取细胞总RNA,RT-PCR扩增BMP-2及BMP-7基因cDNA,同时扩增管家基因βactin作为内对照.扫描PCR产物电泳照片,计算BMP-2/β-actin及BMP-7/-βactin的积分光密度比值,推算BMP-2及BMP-7基因的相对表达水平.结果 IGF-1可以在转录水平增加大鼠成骨细胞中BMP-2及BMP-7基因的表达,并呈明显的剂量依赖关系.结论 IGG-1促进成骨细胞增殖、分化的作用可能是通过增加BMP-2及BMP-7基因的表达来实现的.     

持续给予hPTH1-34对体外成骨细胞增殖与分化的影响

目的研究持续给予人甲状旁腺激素（human parathyroid hormone,hPTH）1-34对体外培养成骨细胞增殖与分化的干预作用。方法体外培养乳鼠成骨细胞,将细胞分为空白培养液对照组和10^-6、10^-7、10^-8mol·L^-1hPTH（1-34）3个不同剂量的给药组。每48h换1次液,换液时采用MTT法进行细胞增殖测定,同时检测细胞裂解液中的碱性磷酸酶（alkaline phosphatase,ALP）和骨钙素（bone gla protein,BGP）的水平,持续培养6d。结果持续给予hPTH1-34作用48h后,各给药组的MTT均明显高于对照组且各给药组间差异均有显著性（P〈0.05）,至第6天时各给药组则均明显低于对照组（P〈0.05）。ALP和BGP测定结果显示持续给予hPTH1-34作用48h后,10^-6mol·L^-1PTH给药组的BGP含量明显高于对照组（P〈0.01）,其余各组ALP及BGP含量与对照组比较差异虽无显著性,但均值高于对照组,至第6天各给药组均明显低于对照组（P〈0.05）。结论持续给予hPTH（1-34）对体外培养成骨细胞增殖与分化的影响与作用的时间和给药浓度密切相关。短期持续用药有促进作用,并且在10^-6-10^-8mol·L^-1浓度范围内呈剂量依赖性;长期持续用药抑制成骨细胞的增殖与分化,给药浓度越高抑制作用越强。     

胰高血糖素样肽-1类似物对人成骨细胞Wnt信号通路相关基因表达的影响

目的 观察胰高血糖素样肽-1类似物（利拉鲁肽）对人成骨细胞增殖及Wnt信号通路相关因子mRNA的表达，探讨胰高血糖素样肽-1(GLP-1)与骨代谢的关系。方法 向体外培养的人成骨细胞中分别加入浓度为0mol/L、10-7mol/L、10-8mol/L、10-9mol/L的GLP-1类似物，24h后采用Cell Counting Kit-8(CCK-8)比色法检测成骨细胞增殖率，实时荧光定量PCR（Real-time RT-PCR）法检测Wnt-3a、LRP-5、β-catenin mRNA 的表达。结果 （1）GLP-1促进人成骨细胞增殖（P<0.05），随着给药浓度的增高，成骨细胞增殖率下降（P<0.05）；（2）低浓度GLP-1（10-9mol/L）上调人成骨细胞中Wnt-3a、LRP-5、β-catenin mRNA 的表达(P<0.05)；高浓度GLP-1（10-7mol/L、10-8mol/L）下调人成骨细胞中Wnt-3a、LRP-5、β-catenin mRNA 的表达(P<0.05)。结论 GLP-1促进人成骨细胞的增殖，低浓度时Wnt信号通路可能参与了该调控过程，高浓度抑制Wnt信号通路相关基因的表达。     

Prevention of atrophic nonunion development by recombinant human bone morphogenetic protein-7.

Severe periosteal and soft tissue disruption at the time of fracture may result in the formation of an atrophic nonunion. We have developed a reproducible atrophic nonunion in an animal model. The purpose of this study was to evaluate whether the immediate application of recombinant human BMP-7 to the fracture site could rescue the healing process in this nonunion model. A total of 56 three month old Fisher 344 rats were utilized. A 1.25 mm diameter K-wire was inserted into the femur in a retrograde fashion, and a mid-diaphyseal closed transverse fracture was created using a standard three point bending device. To create a nonunion, the fracture site was exposed and 2 mm of the periosteum was cauterized on each side of the fracture. The fracture site was immediately treated with either the application of rhBMP-7 50 microg in 25 microl of rat tail tendon collagen buffer (BMP-7 group), or with 25 microl of rat tail tendon collagen buffer only (Control group). Fracture healing was evaluated with serial radiographs every two weeks for an eight weeks period. Specimens at four and eight weeks were subjected to biomechanical and histological evaluation. None of the Control group healed throughout the eight weeks experimental duration. At four weeks 63% of the BMP-7 group had healed, and all had healed by six weeks. This investigation showed pronounced differences between the BMP-7 group and the Control group both histologically and biomechanically. In conclusion, we have demonstrated that the immediate application of BMP-7 may rescue the fracture healing process and prevent the development of nonunion following severe periosteal disruption.     

重组人骨形态发生蛋白-2缓释微球对成骨细胞的作用

目的　探讨甲基丙烯酸缩水甘油酯右旋糖酐 (dex GMA)重组人骨形态发生蛋白(rhBMP 2 )凝胶微球 (rhBMP2 dex HM )对成骨细胞的生物学作用。方法　将单纯rhBMP 2 (A组 )、空白dex GMA凝胶微球dex HM (B组 )和rhBMP2 dex HM (C组 )加入成骨细胞培养液中 ,用细胞计数法、噻唑蓝比色法 (MTT法 )、流式细胞仪观察细胞增殖情况 ,并检测成骨细胞上清液中骨钙素 (BGP)含量。结果　培养 1～ 2d后 ,3组细胞计数、吸光度 (A)值差异无统计学意义 (P >0 .0 5 ) ;4～ 6d时A、C组细胞计数和A值开始高于B组 ,但A、C组间差异无统计学意义 (P >0 .0 5 ) ;培养 6～ 8d后 ,C组明显高于其他组 ,差异有统计学意义 (P <0 .0 1)。14d后 ,A、B、C 3组细胞数分别为 (2 2 .97± 0 .2 3 )、(13 .89± 0 .5 7)和 (3 2 .46± 0 .67)× 10 4个细胞 /ml,差异有统计学意义(P <0 .0 1)。流式细胞仪检测结果显示 ,培养 2d后 ,A组的G2 /M +S期百分数最高 ;6～ 8d后 ,C组的G2 /M +S期百分数最高。成骨细胞上清液中BGP含量 ,C微球组最高 ,其次为A组。结论　rhBMP 2 dex HM可以较长时间持续释放活性rhBMP 2 ,作为rhBMP 2的缓释载体 ,可以明显促进成骨细胞增殖和分化。     

血管内皮生长因子和骨形态发生蛋白7在细胞分化中的协同作用

目的：研究rhVEGF和rhBMP-7对成骨细胞分化能力的影响.方法：取大鼠颅盖骨组织块,采用改良组织块混合酶消化法培养成骨细胞,将不同浓度的rhVEGF和rhBMP-7加入第四代成骨细胞的培养基继续进行细胞培养,用碱性磷酸酶试剂盒检测定细胞在第1、3、5天的磷酸酶的活性,分析不同浓度的rhVEGF和rhBMP-7对成骨细胞分化的影响.结果：rhVEGF和rhBMP-7能促进成骨细胞的分化,其中,3.125ng/mlrhVEGF和50.000ng/ml rhBMP-7单独或者两者联合作用并于第3天时,对成骨细胞碱性磷酸酶活性的影响最明显.结论：一定剂量的rhVEGF和rhBMP-7可明显促进成骨细胞的分化.     

重组人骨形态发生蛋白-2对鼠雪旺细胞增殖及生长相关蛋白GAP-43表达的影响

目的 观察重组入骨形态发生蛋白-2( rhBMP-2)对体外培养的乳鼠雪旺细胞增殖及生长相关蛋白( GAP-43)表达的影响。方法 将纯化的雪旺细胞分两组,一组设为对照,另一种加含终质量浓度为5 μg/L rhBMP-2的DMEM/F12培养液培养,在培养后0、12、24、36、48、72 h分别用噻唑蓝(MTT)比色法检测不同时间点的A值并绘制生长曲线;用BrdU法测定雪旺细胞增殖率;用Western blot法检测GAP-43蛋白的表达水平。结果 经含5μg/L rhBMP-2培养液培养的雪旺细胞,在24、36、48 h细胞增殖率明显高于对照组,差异有统计学意义(P＜0.05);实验组中GAP-43在24、36、48 h的表达也显著高于对照组(P＜0.05)。结论 rhBMP-2有促进雪旺细胞分裂增殖和GAP-43蛋白表达的作用,可能是其促进周围神经再生的重要机制之一。     

BMP-2联合BMP-7在截骨延长时促进成骨的实验研究

目的 探究在截骨延长成骨过程中联合应用BMP-2和BMP-7对成骨的促进作用.方法 采用健康成年日本大耳白兔30只,完全随机分为三组.A组作为对照组正常牵拉不做其他处理;B组在截骨后于截骨处加入rhBMP-2药片;C组在截骨后于截骨处加入rhBMP-2药片,7d后在延长区经皮注射rhBMP-7溶解液.在术后第7天、第3...     

Health economics: a cost analysis of treatment of persistent fracture non-unions using bone morphogenetic protein-7

OBJECTIVE: To compare the cost implications of treatment of persistent fracture non-unions before and after application of recombinant human bone morphogenetic protein-7 (BMP-7). METHOD: Of 25 fracture non-unions, 9 were treated using BMP-7 alone and 16 using BMP-7 and bone grafting. These patients were prospectively followed up, and the costs incurred were analysed. RESULTS: The mean number of procedures per fracture performed before application of BMP-7 was 4.16, versus 1.2 thereafter. Mean hospital stay and cost of treatment per fracture before receiving BMP-7 were 26.84 days and pound 13,844.68, versus 7.8 days and pound 7338.4 thereafter. The overall cost of treatment of persistent fracture non-unions with BMP-7 was 47.0% less than that of the numerous previous unsuccessful treatments (p=0.001). CONCLUSIONS: Treating fracture non-unions is costly, but this could be reduced by early BMP-7 administration when a complex or persistent fracture non-union is present or anticipated.     

Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7

AIM To present the incidence of heterotopic ossification after the use of recombinant human bone morphogenetic protein-7(rhB MP-7) for the treatment of nonunions.METHODS Bone morphogenetic proteins(BMPs) promote bone formation by auto-induction. Recombinant human BMP-7 in combination with bone grafts was used in 84 patients for the treatment of long bone nonunions. All patients were evaluated radiographicaly for the development of heterotopic ossification during the standard assessment for the nonunion healing. In all patients(80.9%) with radiographic signs of heterotopic ossification, a CT scan was performed. Nonunion site palpation and ROM evaluation of the adjacent jointswere also carried out. Factors related to the patient(age, gender), the nonunion(location, size, chronicity, number of previous procedures, infection, surrounding tissues condition) and the surgical procedure(graft and fixation type, amount of rhB MP-7) were correlated with the development of heterotopic ossification and statistical analysis with Pearsons χ~2 test was performed.RESULTS Eighty point nine percent of the nonunions treated with rh BMP-7, healed with no need for further procedures. Heterotopic bone formation occurred in 15 of 84 patients(17.8%) and it was apparent in the routine radiologi-cal evaluation of the nonunion site, in a mean time of 5.5 mo after the rh BMP-7 application(range 3-12). The heterotopic ossification was located at the femur in 8 cases, at the tibia in 6, and at the humerus in οne patient. In 4 patients a palpable mass was present and only in one patient, with a para-articular knee nonunion treated with rhB MP-7, the size of heterotopic ossification affected the knee range of motion. All the patients with heterotopic ossification were male. Statistical analysis proved that patient's gender was the only important factor for the development of heterotopic ossification(P = 0.007). CONCLUSION Heterotopic ossification after the use of rh BMP-7 in nonunions was common but it did not compromise the final clinical outcome in most cases, and affected only male patients.     

rhBMP-2对骨骼肌卫星细胞增殖与粘附的影响

目的探讨人重组骨形态发生蛋白(rhBMP)-2对骨骼肌卫星细胞增殖与粘附的影响.方法体外分离与培养骨骼肌卫星细胞,分别用0、50、100、500、1000 ng/ml的rhBMP-2诱导培养基培养48h.利用MTT法测定细胞增殖能力的变化,通过荧光法测定接种后1h的粘附细胞率.结果rhBMP-2可促进骨骼肌卫星细胞的增殖,这种作用从BMP浓度为500ng/ml即可表现出来,并随着浓度的增加而越发明显.在rhBMP-2作用下骨骼肌卫星细胞的粘附率增高,在500ng/ml的浓度时达最高,但当BMP浓度进一步增大时,细胞粘附率却不再增加.结论rhBMP-2可促进骨骼肌卫星细胞的增殖,增强其粘附特性.